Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.68 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.64 |
| ▸ | CHUK | O15111 | 2/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | DKK1 | O94907 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13440366 | 0.87 | PIK3CA (0.66) | IKBKBCHUKPTGS2MAPK8MAPK10 | |
| SCHEMBL3518683 | 0.84 | IKBKB (0.66) | IKBKBMAPK8MAPK10ABL1DKK1 | |
| SCHEMBL3753792 | 0.83 | PTGS2 (0.67) | IKBKBCHUKJAK2JAK3PTGS2 | |
| SCHEMBL3758490 | 0.83 | IKBKB (0.66) | IKBKBCHUKMAPK8MAPK10DKK1 | |
| SCHEMBL3519764 | 0.83 | IKBKB (0.97) | IKBKBCHUKJAK2MAPK8MAPK10 | |
| SCHEMBL1593016 | 0.82 | PRKCD (0.79) | IKBKBCAMK2DJAK2JAK3MAPK8 | |
| SCHEMBL3759245 | 0.82 | AURKA (0.66) | IKBKBCHUKMAPK8MAPK10 | |
| SCHEMBL24334967 | 0.82 | PTGS2 (0.64) | IKBKBPTGS2 | |
| SCHEMBL3760561 | 0.81 | MAPK8 (0.64) | IKBKBCAMK2DCHUKJAK2MAPK8 | |
| SCHEMBL3747898 | 0.81 | IKBKB (0.56) | IKBKBCAMK2DCHUKJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2200436-B1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2200436-B1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | IKBKB 288/4885CAMK2D 385/4885CHUK 44/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | IKBKB 288/4885CAMK2D 385/4885CHUK 44/4885 |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | IKBKB 288/4885CAMK2D 385/4885CHUK 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.